Welcome to Eurofins Advinus
A premier preclinical and development stage contract research company for regulatory Toxicology (Safety Assessment), CMC services, DMPK and Analytical R&D Services. With over 30 years of GLP compliance and certification, Eurofins Advinus serves diverse industries such as Biotech, Pharmaceutical, Biological, Agrochemical, Nutraceutical and Cosmetic. Eurofins Advinus is the only contract research organization (CRO) in India to have developed data in support of 70+ end-to-end IND enabling packages to be submitted to global regulators such as USFDA, EMA, MHRA, Health Canada and others.
EUROFINS ADVINUS' ACHIEVEMENTS
YEARS OF
GLP EXPERIENCE
IND PACKAGES
CARCINOGENICITY STUDIES
REGULATORY STUDIES
FACILITY TOUR
NEWS AND EVENTS
Eurofins announces acquisition of assets of Gomti Life Sciences
Eurofins, through Eurofins Advinus, acquires all assets of Gomti Life… more
Eurofins Advinus Diwali Celebration
Eurofins Advinus Diwali celebrations... rangoli and traditional wear add colour… more
Eurofins Advinus at BIO International Convention - 2019 , Philadelphia, USA
Eurofins Advinus at 2019 - BIO International Convention, Philadelphia, USA more
Eurofins is a 2019 CRO Award Winner
Eurofins has proudly been a winner of the CRO Leadership… more
CASE STUDIES - SEE HOW OUR SCIENCE CAN DRIVE YOUR RESEARCH & DEVELOPMENT
WHAT OUR CLIENTS SAY
-
The Eurofins Advinus team…
The Eurofins Advinus team has shown excellent performance in progressing the chemistry and delivering critical compounds which have helped us in advancing the project and answering very pertinent hypothesis to understand the SAR. The team deserves appreciation for meeting deliverables par excellence, even through the scale-up synthesis in a brief period with high quality and purity for advancing in-vivo-studies.
Dr. Shahul Hameed, Chief Product Officer, Bugworks Research Inc
-
We are happy to…
We are happy to work with the Eurofins Advinus team since the beginning of our project. We find professionalism, reactivity and proactivity in anticipating potential issues and resolving them in short time. The asset produced meets international standards of quality (non GMP and GMP).
Stephane Paris, Scientific R&D Project Manager, PMP, Accure Tx
-
We have had an…
We have had an excellent partnership with Eurofins Advinus for over 6 years. During this period, we have performed several IND enabling studies that were accepted by the regulatory agencies (US-FDA, HC, EMA) and these programs are currently undergoing PoC clinical trials. In addition, post IND we have conducted subchronic and chronic toxicity studies including genetic toxicity, DART and carcinogenicity studies each supported with excellent analytical and bioanalytical capabilities. We are extremely happy with the proficiency of the team and the quality of data meets the international standards. We are pleased with the services provided by Eurofins Advinus and look forward to our continued collaboration.
Dr. Mahesh Mistry, Director Toxicology
-
I am pleased to…
I am pleased to announce that the U.S. Food and Drug Administration (FDA) has cleared 7 Hills Pharma’s investigational new drug (IND) application for 7HP349, a first-in-class, oral integrin activator for solid tumors. A large part of the preclinical development work comprising CMC, ADME/DMPK and toxicology/safety assessment was outsourced to Eurofins Advinus Limited, Bangalore, India. We are pleased with the experience, professionalism, capability and enthusiasm of the Advinus team in completing this work. Their professionalism, understanding of regulatory requirements, and drive to resolve complexities faced during the 7HP349 preclinical development program in ADME, formulation development, toxicology and process development contributed significantly to the timely preparation of a comprehensive and compelling IND application to the FDA. It is my pleasure to recommend Advinus for preclinical drug development and IND-enabling studies.
Upendra Marathi, Co-founder, President & CEO, 7 Hills Pharma LLC,Houston, TX